On November 22, Gelonghui reported that Shenzhen Salubris Pharmaceuticals Co., Ltd. intends to increase its investment in Peking Purui Benchmark Technology Co., Ltd. (hereinafter referred to as "Purui Benchmark" or "symbol company") with self-raised capital of 30 million yuan, obtaining 3.2154% of the private equity. After this capital increase is completed, the company will directly hold 8.5745% of the private equity in Purui Benchmark.

Before the capital increase, the company and its subsidiary holding enterprises, Ningbo Meishan Bonded Port Area Wosheng Jingjia Private Equity Investment Partnership (Limited Partnership) (hereinafter referred to as "Wosheng Jingjia"), as well as its subsidiary investments in "Pingtan Comprehensive Experimental Zone Wosheng Huijia Private Equity Investment Partnership (Limited Partnership)" (hereinafter referred to as "Wosheng Huijia"), held 5.5556%, 3.8332%, and 2.3666% of the private equity in Purui Benchmark respectively.